Moderna Is the COVID Vaccine Front-Runner
Moderna is currently the front-runner in developing a coronavirus vaccine. They will be entering the third phase of clinical trials this month with about 30,000 people participating. While there is a lot of hope riding on Moderna to come through, the company has no track record in developing an approved drug and is also using an unproven approach to making the vaccine. Still, the company is worth $24 billion because of its current work. Peter Loftus, reporter at the WSJ, joins us for more on vaccine front-runner, Moderna.
Learn more about your ad-choices at https://news.iheart.com/podcast-advertisers